{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:56:48Z","timestamp":1777712208612,"version":"3.51.4"},"reference-count":89,"publisher":"Georg Thieme Verlag KG","issue":"04","funder":[{"DOI":"10.13039\/501100006126","name":"The Hospital for Sick Children","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006126","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr Surg"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The novel coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), continues to be a major health concern. In search for novel treatment strategies against COVID-19, exosomes have attracted the attention of scientists and pharmaceutical companies worldwide. Exosomes are small extracellular vesicles, secreted by all types of cells, and considered as key mediators of intercellular communication and stem-cell paracrine signaling. Herein, we reviewed the most recent literature about the role of exosomes as potential agents for treatment, prevention, diagnosis, and pathogenesis of COVID-19. Several studies and ongoing clinical trials have been investigating the anti-inflammatory, immunomodulatory, and reparative effects of exosomes derived from mesenchymal stem\/stromal cells for COVID-19-related acute lung injury. Other studies reported that exosomes play a key role in convalescent plasma therapy for COVID-19, and that they could be of use for the treatment of COVID-19 Kawasaki's-like multisystem inflammatory syndrome and as drug delivery nanocarriers for antiviral therapy. Harnessing some advantageous aspects of exosome biology, such as their endogenous origin, capability of crossing biological barriers, high stability in circulation, and low toxicity and immunogenicity, several companies have been testing exosome-based vaccines against SARS-CoV-2. As they carry cargos that mimic the status of parent cells, exosomes can be isolated from a variety of sources, including plasma, and employed as biomarkers of COVID-19. Lastly, there is growing evidence supporting the role of exosomes in COVID-19 infection, spread, reactivation, and reinfection. The lessons learned using exosomes for COVID-19 will help determine their efficacy and applicability in other clinical conditions.<\/jats:p>","DOI":"10.1055\/s-0041-1731294","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T22:47:48Z","timestamp":1624488468000},"page":"326-334","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-19"],"prefix":"10.1055","volume":"31","author":[{"given":"Elke","family":"Zani-Ruttenstock","sequence":"additional","affiliation":[{"name":"Division of General and Thoracic Surgery, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Antounians","sequence":"additional","affiliation":[{"name":"Division of General and Thoracic Surgery, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasra","family":"Khalaj","sequence":"additional","affiliation":[{"name":"Division of General and Thoracic Surgery, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca L.","family":"Figueira","sequence":"additional","affiliation":[{"name":"Division of General and Thoracic Surgery, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto","family":"Zani","sequence":"additional","affiliation":[{"name":"Division of General and Thoracic Surgery, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Developmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Surgery, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"F Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"F Wu","year":"2020","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"109865","DOI":"10.1016\/j.mehy.2020.109865","article-title":"Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes","volume":"144","author":"M Taghavi-Farahabadi","year":"2020","journal-title":"Med Hypotheses"},{"key":"ref4","volume-title":"Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19)","author":"M Cascella","year":"2021"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"M Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"07","key":"ref6","first-page":"e00127","article-title":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Y Wan","year":"2020","journal-title":"J Virol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"H Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Z Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"N Chen","year":"2020","journal-title":"Lancet"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/cid\/ciaa272","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","volume":"71","author":"Z Wang","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"D Wang","year":"2020","journal-title":"JAMA"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12519-020-00392-y","article-title":"Why COVID-19 is less frequent and severe in children: a narrative review","volume":"17","author":"R Sinaei","year":"2021","journal-title":"World J Pediatr"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"2001617","DOI":"10.1183\/13993003.01617-2020","article-title":"Will children reveal their secret? The coronavirus dilemma","volume":"55","author":"F Midulla","year":"2020","journal-title":"Eur Respir J"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2352-4642(20)30165-6","article-title":"Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children","volume":"4","author":"L Tullie","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"e12004","DOI":"10.1002\/jev2.12004","article-title":"COVID-19 therapy with mesenchymal stromal cells (MSC) and convalescent plasma must consider exosome involvement: Do the exosomes in convalescent plasma antagonize the weak immune antibodies?","volume":"10","author":"P W Askenase","year":"2020","journal-title":"J Extracell Vesicles"},{"issue":"08","key":"ref18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/pharmaceutics11080404","article-title":"Extracellular vesicles as a potential therapy for neonatal conditions: state of the art and challenges in clinical translation","volume":"11","author":"A C Matei","year":"2019","journal-title":"Pharmaceutics"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7150\/thno.21945","article-title":"Exosome theranostics: biology and translational medicine","volume":"8","author":"C He","year":"2018","journal-title":"Theranostics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"R Kalluri","year":"2020","journal-title":"Science"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1083\/jcb.201212113","article-title":"Exosomes: looking back three decades and into the future","volume":"200","author":"C V Harding","year":"2013","journal-title":"J Cell Biol"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.healun.2016.01.013","article-title":"Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure","volume":"35","author":"A Kervadec","year":"2016","journal-title":"J Heart Lung Transplant"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41598-018-38320-w","article-title":"The regenerative potential of amniotic fluid stem cell extracellular vesicles: lessons learned by comparing different isolation techniques","volume":"9","author":"L Antounians","year":"2019","journal-title":"Sci Rep"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"1795365","DOI":"10.1080\/20013078.2020.1795365","article-title":"Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19?","volume":"9","author":"K Khalaj","year":"2020","journal-title":"J Extracell Vesicles"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"P Mehta","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S1473-3099(20)30312-1","article-title":"Plea for multitargeted interventions for severe COVID-19","volume":"20","author":"B J Gaborit","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4049\/jimmunol.179.3.1855","article-title":"Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice","volume":"179","author":"N Gupta","year":"2007","journal-title":"J Immunol"},{"issue":"38","key":"ref28","doi-asserted-by":"crossref","first-page":"16357","DOI":"10.1073\/pnas.0907996106","article-title":"Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung","volume":"106","author":"J W Lee","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/thoraxjnl-2015-206813","article-title":"Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat","volume":"70","author":"J Devaney","year":"2015","journal-title":"Thorax"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13287-016-0320-5","article-title":"The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo","volume":"7","author":"S Hu","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2347938","DOI":"10.1155\/2016\/2347938","article-title":"The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo","volume":"2016","author":"Y Yang","year":"2016","journal-title":"Mediators Inflamm"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1097\/CCM.0000000000002073","article-title":"Cryopreserved, xeno-free human umbilical cord mesenchymal stromal cells reduce lung injury severity and bacterial burden in rodent escherichia coli-induced acute respiratory distress syndrome","volume":"45","author":"G F Curley","year":"2017","journal-title":"Crit Care Med"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1164\/rccm.201701-0107CP","article-title":"Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value","volume":"196","author":"J G Laffey","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"4236973","DOI":"10.1155\/2019\/4236973","article-title":"Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives","volume":"2019","author":"C R Harrell","year":"2019","journal-title":"Stem Cells Int"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume":"103","author":"R Meisel","year":"2004","journal-title":"Blood"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/leu.2010.310","article-title":"Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase","volume":"25","author":"R Meisel","year":"2011","journal-title":"Leukemia"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1038\/srep07820","article-title":"Mesenchymal stem cells detect and defend against gammaherpesvirus infection via the cGAS-STING pathway","volume":"5","author":"K Yang","year":"2015","journal-title":"Sci Rep"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"860950","DOI":"10.1155\/2015\/860950","article-title":"Mesenchymal stromal cells and viral infection","volume":"2015","author":"M Thanunchai","year":"2015","journal-title":"Stem Cells Int"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/17476348.2020.1679628","article-title":"The potential of mesenchymal stem cell therapy for chronic lung disease","volume":"14","author":"F F Cruz","year":"2020","journal-title":"Expert Rev Respir Med"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/ALN.0000000000002653","article-title":"Is a part better than the whole for cell-based therapy for acute respiratory distress syndrome?","volume":"130","author":"J W Lee","year":"2019","journal-title":"Anesthesiology"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"L1107","DOI":"10.1152\/ajplung.00391.2018","article-title":"Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats","volume":"316","author":"Q C Li","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"eaax5941","DOI":"10.1126\/scitranslmed.aax5941","article-title":"Fetal lung underdevelopment is rescued by administration of amniotic fluid stem cell extracellular vesicles in rodents","volume":"13","author":"L Antounians","year":"2021","journal-title":"Sci Transl Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"30087","DOI":"10.3402\/jev.v4.30087","article-title":"Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper","volume":"4","author":"T Lener","year":"2015","journal-title":"J Extracell Vesicles"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCRESAHA.115.306593","article-title":"Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration","volume":"117","author":"S G Ong","year":"2015","journal-title":"Circ Res"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13287-018-0774-8","article-title":"Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model","volume":"9","author":"M Khatri","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40169-019-0242-9","article-title":"Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options","volume":"8","author":"T G Shah","year":"2019","journal-title":"Clin Transl Med"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/scd.2020.0080","article-title":"Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19","volume":"29","author":"V Sengupta","year":"2020","journal-title":"Stem Cells Dev"},{"issue":"14","key":"ref48","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/scd.2020.0089","article-title":"Re: \u201cexosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19\u201d by Sengupta et al","volume":"29","author":"S K Lim","year":"2020","journal-title":"Stem Cells Dev"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3402\/jev.v3.23743","article-title":"Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood","volume":"3","author":"L Cheng","year":"2014","journal-title":"J Extracell Vesicles"},{"issue":"16","key":"ref50","doi-asserted-by":"crossref","first-page":"9439","DOI":"10.1111\/jcmm.15606","article-title":"Association of plasma exosomes with severity of organ failure and mortality in patients with sepsis","volume":"24","author":"Y Im","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"L Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.03.407031","article-title":"Circulating ACE2-expressing exosomes block SARS-CoV-2 infection as an innate antiviral mechanism","author":"L El-Shennawy","year":"2020","journal-title":"bioRxiv"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.120.048360","article-title":"Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic","volume":"142","author":"Z Belhadjer","year":"2020","journal-title":"Circulation"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","article-title":"Hyperinflammatory shock in children during COVID-19 pandemic","volume":"395","author":"S Riphagen","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"ref55","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/hpeds.2020-000356","article-title":"COVID-19 and Kawasaki disease: finding the signal in the noise","volume":"10","author":"A R Schroeder","year":"2020","journal-title":"Hosp Pediatr"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"L Verdoni","year":"2020","journal-title":"Lancet"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00431-020-03766-6","article-title":"Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach","volume":"180","author":"F Sperotto","year":"2021","journal-title":"Eur J Pediatr"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"632890","DOI":"10.3389\/fimmu.2021.632890","article-title":"Phenotype, susceptibility, autoimmunity, and immunotherapy between Kawasaki disease and coronavirus disease-19 associated multisystem inflammatory syndrome in children","volume":"12","author":"M R Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/bies.201100076","article-title":"Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers","volume":"33","author":"S Lakhal","year":"2011","journal-title":"BioEssays"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","article-title":"Extracellular vesicles for drug delivery","volume":"106","author":"P Vader","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"01","key":"ref61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12015-020-10002-z","article-title":"Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19","volume":"17","author":"G S Pinky","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"05","key":"ref62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/v12050486","article-title":"Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19","volume":"12","author":"S Kumar","year":"2020","journal-title":"Viruses"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"e2014","DOI":"10.1002\/rmv.2014","article-title":"Influenza vaccine: where are we and where do we go?","volume":"29","author":"M Keshavarz","year":"2019","journal-title":"Rev Med Virol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3389\/fcimb.2020.00366","article-title":"Role of extracellular vesicles in influenza virus infection","volume":"10","author":"Y Jiang","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"02","key":"ref65","first-page":"94","article-title":"Promising extracellular vesicle-based vaccines against viruses, including SARS-CoV-2","volume":"10","author":"B Sabanovic","year":"2021","journal-title":"Biology (Basel)"},{"issue":"27","key":"ref66","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"F P Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/d41573-020-00220-y","article-title":"Exosome-based candidates move into the clinic","volume":"20","author":"M Cully","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"C Th\u00e9ry","year":"2018","journal-title":"J Extracell Vesicles"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1159\/000511402","article-title":"COVID-19 and extracellular vesicles: an intriguing interplay","volume":"45","author":"G Pocsfalvi","year":"2020","journal-title":"Kidney Blood Press Res"},{"issue":"02","key":"ref70","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11481-020-09981-0","article-title":"A role for extracellular vesicles in SARS-CoV-2 therapeutics and prevention","volume":"16","author":"J Machhi","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3390\/ijms22031142","article-title":"Membrane microvesicles as potential vaccine candidates","volume":"22","author":"L Shkair","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/atm.2016.12.75","article-title":"A novel role of exosomes in the vaccination approach","volume":"5","author":"P B Devhare","year":"2017","journal-title":"Ann Transl Med"},{"issue":"07","key":"ref73","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/eji.200535615","article-title":"Direct exosome stimulation of peripheral human T cells detected by ELISPOT","volume":"36","author":"C Admyre","year":"2006","journal-title":"Eur J Immunol"},{"issue":"05","key":"ref74","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40259-020-00434-x","article-title":"Designer exosomes: a new platform for biotechnology therapeutics","volume":"34","author":"D Jafari","year":"2020","journal-title":"BioDrugs"},{"issue":"12","key":"ref75","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.4049\/jimmunol.1600731","article-title":"CD63-mediated antigen delivery into extracellular vesicles via dna vaccination results in robust CD8+ T cell responses","volume":"198","author":"T Kanuma","year":"2017","journal-title":"J Immunol"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"e1700443","DOI":"10.1002\/biot.201700443","article-title":"An exosome-based vaccine platform imparts cytotoxic T lymphocyte immunity against viral antigens","volume":"13","author":"S Anticoli","year":"2018","journal-title":"Biotechnol J"},{"issue":"01","key":"ref77","first-page":"245","article-title":"Immunogenic potency of engineered exosomes for prevention of respiratory syncytial virus","volume":"204","author":"S Hong","year":"2020","journal-title":"J Immunol"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virol.2006.12.011","article-title":"Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies","volume":"362","author":"S Kuate","year":"2007","journal-title":"Virology"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.06.371419","article-title":"Exosome-mediated mRNA delivery for SARS-CoV-2 vaccination","author":"J S Tsai","year":"2020","journal-title":"bioRxiv"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.28.357137","article-title":"Extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-SARS-CoV-2 response in mice","author":"K Polak","year":"2020","journal-title":"bioRxiv"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1742-2094-11-68","article-title":"Exosomes as mediators of neuroinflammation","volume":"11","author":"A Gupta","year":"2014","journal-title":"J Neuroinflammation"},{"issue":"02","key":"ref85","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cmet.2020.06.016","article-title":"Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis","volume":"32","author":"J W Song","year":"2020","journal-title":"Cell Metab"},{"issue":"02","key":"ref86","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/cells10020386","article-title":"Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations","volume":"10","author":"B Sun","year":"2021","journal-title":"Cells"},{"issue":"01","key":"ref87","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.blre.2012.12.002","article-title":"Extracellular vesicles in physiological and pathological conditions","volume":"27","author":"Y Yuana","year":"2013","journal-title":"Blood Rev"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/2049-632X.12135","article-title":"The carrying pigeons of the cell: exosomes and their role in infectious diseases caused by human pathogens","volume":"71","author":"A Fleming","year":"2014","journal-title":"Pathog Dis"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"104422","DOI":"10.1016\/j.meegid.2020.104422","article-title":"The role of extracellular vesicles in COVID-19 virus infection","volume":"85","author":"M Hassanpour","year":"2020","journal-title":"Infect Genet Evol"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/jmv.25855","article-title":"False negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: rather than recurrence","volume":"92","author":"A T Xiao","year":"2020","journal-title":"J Med Virol"},{"issue":"05","key":"ref91","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jinf.2020.03.001","article-title":"Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation","volume":"80","author":"G Ye","year":"2020","journal-title":"J Infect"},{"issue":"16","key":"ref92","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/cid\/ciaa398","article-title":"Polymerase chain reaction assays reverted to positive in 25 discharged patients with COVID-19","volume":"71","author":"J Yuan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1790426","article-title":"On the potential role of exosomes in the COVID-19 reinfection\/reactivation opportunity","author":"F Elrashdy","year":"2020","journal-title":"J Biomol Struct Dyn"}],"container-title":["European Journal of Pediatric Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1731294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T07:54:16Z","timestamp":1699170856000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1731294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":89,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,7,9]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1731294","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0939-7248","1439-359X"],"issn-type":[{"value":"0939-7248","type":"print"},{"value":"1439-359X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]}}}